Kazia Therapeutics Limited
KZIA · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | -0.02 | 0.02 |
| FCF Yield | -34.64% | -34.65% | -40.00% | -16.00% |
| EV / EBITDA | -2.19 | -0.45 | -1.59 | -3.79 |
| Quality | ||||
| ROIC | -308.00% | 275.65% | -33.63% | -48.01% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.81 | 0.18 | 0.72 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.67% | 0.73% | -93.48% | -86.47% |
| Free Cash Flow Growth | -29.70% | 48.76% | 0.24% | 27.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | 0.05 | 0.40 | 0.36 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 714.23 | 4.82 | 1,177,074.00 | 98.92 |